Form 4: Natera Co-Founder Sells Shares via 10b5-1 Plan

Natera Co-Founder Jonathan Sheena sold 1,500 shares of common stock through pre-arranged trading plans on December 19, 2025.

Summary

• Jonathan Sheena, a Co-Founder and Director of Natera, Inc. (NTRA), reported sales of common stock.
• A total of 1,500 shares were sold on December 19, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 7, 2024.
• The shares were sold at weighted average prices ranging from $224.741 to $226.3592 per share.
• The sales were made indirectly through the Caraluna 1 Trust and Caraluna 2 Trust.
• Following these transactions, Jonathan Sheena directly beneficially owns 222,966 shares of common stock.
• The Caraluna 1 Trust holds 22,532 shares and the Caraluna 2 Trust holds 22,532 shares after the reported sales.
• Jonathan Sheena disclaims beneficial ownership over the securities held by the trusts.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider sale executed under a pre-arranged 10b5-1 plan, which is a common practice and does not inherently indicate a positive or negative outlook on the company's future. The disclaimer of beneficial ownership over trust assets is also standard.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive disposition of shares, which is a common practice for insider liquidity or diversification.

Negatives

• A Co-Founder and Director is reducing their indirect stake in the company, which could be perceived as a slight negative signal by some investors.

Risks

• Insider sales, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence or a desire to diversify holdings, which could lead to short-term price volatility.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past insider transactions.

Management Comments

• The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
• The Reporting Person disclaims beneficial ownership over such securities [held for the benefit of the beneficiaries of the trust].

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape. Insider sales are common for diversification or liquidity purposes, especially when executed under pre-planned trading arrangements.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of insider trading activity. There are no specific company or project results to compare against industry benchmarks.
• The execution of sales via a 10b5-1 plan is a common practice among executives to mitigate accusations of trading on material non-public information, aligning with best practices for insider trading compliance.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, though the 10b5-1 plan mitigates this concern. The overall impact on share price is likely minimal given the small volume relative to total shares outstanding and the pre-planned nature.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the execution of the pre-planned sales.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale by a Co-Founder and Director, Jonathan Sheena, executed under a pre-arranged Rule 10b5-1 trading plan. While insider sales can sometimes be viewed negatively, the pre-planned nature suggests a diversification or liquidity event rather than a reaction to new material information. The volume of shares sold (1,500) is relatively small compared to the total shares outstanding and the insider's remaining holdings. Therefore, this specific filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is maintained, pending further fundamental analysis of Natera's operational and financial performance.

Keywords

Natera, NTRA, Insider Sale, Form 4, Jonathan Sheena, 10b5-1 Plan, Director, Co-Founder, Stock Sale